Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

MNG526

842656ae-4cf0-5bce-b0bb-08bdc862f9c1

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
cancer_type_detailed
subtype

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.323
  • HEME_METABOLISM+0.260
  • UV_RESPONSE_DN+0.251
  • TGF_BETA_SIGNALING+0.223
  • PEROXISOME+0.197
  • BILE_ACID_METABOLISM+0.183
  • ANDROGEN_RESPONSE+0.178
  • ESTROGEN_RESPONSE_EARLY+0.172
  • HEDGEHOG_SIGNALING+0.128
  • MITOTIC_SPINDLE+0.124

Top 10 suppressed

  • ANGIOGENESIS-0.414
  • IL6_JAK_STAT3_SIGNALING-0.384
  • E2F_TARGETS-0.368
  • TNFA_SIGNALING_VIA_NFKB-0.368
  • G2M_CHECKPOINT-0.367
  • OXIDATIVE_PHOSPHORYLATION-0.354
  • INFLAMMATORY_RESPONSE-0.340
  • MTORC1_SIGNALING-0.316
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.303
  • MYC_TARGETS_V2-0.263

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG699
mng-umap@100
0.835
2MNG320
mng-umap@100
0.820
3TCGA-E2-A15P-01A-11R-A115-07
breast-umap@18
B0.814
4TCGA-86-8073-01A-11R-2241-07
lung-landscapes@6
cohortA10.786
5SRR1313106
breast-umap@18
B0.781
6TCGA-44-6147-01A-11R-A278-07
lung-landscapes@6
cohortMD20.773
7MNG1049
mng-umap@100
0.772
8TCGA-44-6146-01A-11R-A278-07
lung-landscapes@6
cohortA10.768
9TCGA-OR-A5JW-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.766
10TCGA-E2-A1IL-01A-11R-A14D-07
breast-umap@18
B0.765

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 16 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.323Remibrutinib— uncovered
HEME_METABOLISM0.260Temsirolimus— uncovered
UV_RESPONSE_DN0.251Inavolisib— uncovered
TGF_BETA_SIGNALING0.223Inavolisib— uncovered
PEROXISOME0.197Idelalisib— uncovered
BILE_ACID_METABOLISM0.183Inavolisib— uncovered
ANDROGEN_RESPONSE0.178Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.172Inavolisib— uncovered
HEDGEHOG_SIGNALING0.128Inavolisib— uncovered
MITOTIC_SPINDLE0.124Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.101Inavolisib— uncovered
APICAL_JUNCTION0.063Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.061Inavolisib— uncovered
APICAL_SURFACE0.029Temsirolimus— uncovered
NOTCH_SIGNALING0.019Inavolisib— uncovered
ADIPOGENESIS0.010Inavolisib— uncovered